2023
Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults
Hanseeuw B, Jacobs H, Schultz A, Buckley R, Farrell M, Guehl N, Becker J, Properzi M, Sanchez J, Quiroz Y, Vannini P, Sepulcre J, Yang H, Chhatwal J, Gatchel J, Marshall G, Amariglio R, Papp K, Rentz D, Normandin M, Price J, Healy B, El Fakhri G, Sperling R, Johnson K. Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults. Neurology 2023, 101: e2533-e2544. PMID: 37968130, PMCID: PMC10791053, DOI: 10.1212/wnl.0000000000207962.Peer-Reviewed Original ResearchConceptsAssociated with cognitive declineOlder adultsNon-AD pathologyCognitive declineHippocampal volumeCognitive dataPreclinical Alzheimer Cognitive CompositeInferior temporal tauProspective cohort studyClinically normal older adultsHarvard Aging Brain StudyPittsburgh compound B PET scansOvert cognitive impairmentAnalyzed dataNormal older adultsAging Brain StudyClinically normal adultsLongitudinal associationsAlzheimer's diseaseCohort studyMemory impairmentCognitive compositeCognitive impairmentHippocampal atrophyCognition
2021
Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease
Mayblyum D, Becker J, Jacobs H, Buckley R, Schultz A, Sepulcre J, Sanchez J, Rubinstein Z, Katz S, Moody K, Vannini P, Papp K, Rentz D, Price J, Sperling R, Johnson K, Hanseeuw B. Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. Neurology 2021, 96: e2933-e2943. PMID: 33952655, PMCID: PMC8253562, DOI: 10.1212/wnl.0000000000012108.Peer-Reviewed Original ResearchPreclinical Alzheimer's diseaseCognitive declineHarvard Aging Brain StudyPreclinical Alzheimer Cognitive CompositePrevention trialsAlzheimer's diseaseAging Brain StudyClinically normal adultsPittsburgh compound B (PiB)-PETProspective cohort studyClass II evidenceCompound B (PiB)-PETCognitive compositeIsthmus cingulateIncrease of statistical powerStructural MRICognitive evaluationBackward stepwise regressionEntorhinal cortexHigher amyloidFDG-PETBrain studiesLinear mixed-effects modelsFollow-upCohort study
2019
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease
Hanseeuw B, Betensky R, Jacobs H, Schultz A, Sepulcre J, Becker J, Cosio D, Farrell M, Quiroz Y, Mormino E, Buckley R, Papp K, Amariglio R, Dewachter I, Ivanoiu A, Huijbers W, Hedden T, Marshall G, Chhatwal J, Rentz D, Sperling R, Johnson K. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. JAMA Neurology 2019, 76: 915-924. PMID: 31157827, PMCID: PMC6547132, DOI: 10.1001/jamaneurol.2019.1424.Peer-Reviewed Original ResearchMild cognitive impairmentOlder adultsChoice of outcome measuresPreclinical Alzheimer Cognitive CompositeCognitive impairmentAssociated with cognitive changesProspective cohort studyClinically normal participantsCognitive changesAssociated with subsequent changesMeasure cognitive changeHarvard Aging Brain StudyMeasured 7 yearsPreclinical Alzheimer's diseaseAging Brain StudyPittsburgh compound B PETAlzheimer's diseaseNormal older adultsPrevention trialsOutcome measuresSerial mediation modelCohort studyInclusion criteriaCompound B PETCognitive composite